Raptor Phase 3 Trials Begin

Raptor Pharmaceuticals in the USA have completed the recruitment of 30 patients for phase three trials of their new slow release Cysteamine-based drug that they hope will offer a significant improvement to the lives of Cystinotics. The trials will last for eight weeks and Raptor hope to have the results available by the end of quarter one of 2011. It is not known when the new drug will actually hit the market.

The new treatment is based on an enteric coating that means the active component of the medicine is able to reach the small intestine, where it is more effectively absorbed by the body. Early trials had shown significantly improved results in Cystinotic patients taking the drug every 12 hours, compared to every 6 hours for Cystagon (the current main treatment for Cystinosis).

This is an exciting period for the Cystinosis community, but it should be remembered that the drug is still in the trial phase and it could be some time before the treatment is released.

You can read more at Raptor’s website.

For more background on Raptor’s work, see our 2010 International Conference Report.

Comments are closed.

New Cystinosis Study – CTNS Nonsense Mutation Screen The McGill University in Canada is looking for participants in Europe and North America for a [...] Read more...
Cystinosis Education Day, 19th September 2017 A ‘Cystinosis Patient and Clinician Education Day’ is being held on Tuesday 19th [...] Read more...
Derby Moor Student an Inspiration to Us All Derby Moor student Eeshar Seehra was thrilled to achieve 3 A Levels in Maths, Physics and [...] Read more...
Newsletter – November 2012 Issue 21 of the Foundation newsletter has recently been finalised and is available to download [...] Read more...
All website content copyright Cystinosis Foundation UK (Charity No.1074885) 1997-2013, except where explicitly stated.
Data Protection Act Registration Number: Z9880997. Please refer to our terms and conditions and our privacy policy.
site:bonnyday